Bear of the Day: Elevance Health (ELV)

Elevance Health (ELV) reported weak quarterly results, missing EPS estimates by over 3% and underperforming the S&P 500 with a 15% stock decline in 2025. The company significantly trimmed its 2025 adjusted EPS guidance from the previously reaffirmed range of $34.15 - $34.85, attributing the cut to elevated cost trends in ACA and Medicaid. This has prompted analysts to adopt a bearish stance, leading to negative earnings estimate revisions and a Zacks Rank #5 (Strong Sell) for ELV.

Analysis

Elevance Health (ELV) is facing significant profitability challenges, as evidenced by its latest quarterly results where adjusted EPS fell 13% year-over-year and missed consensus estimates by over 3%. The primary driver for this weakness is cited as industry-wide elevated cost trends within its ACA and Medicaid businesses. This has led management to make a notable cut to its 2025 adjusted EPS guidance, moving it well below the previously reaffirmed range of $34.15 - $34.85, a reversal that suggests a rapid deterioration of operating conditions. This negative earnings outlook has contributed to the stock's significant underperformance, with a 15% loss in 2025 starkly contrasting the S&P 500's 14.6% gain. Despite these margin pressures, the company's top-line remains robust, with sales growing 14% to $49.4 billion, indicating that while demand is strong, the ability to translate revenue into profit is currently impaired. The confluence of negative earnings revisions and the sharp guidance cut has solidified a bearish analyst consensus, reflected in the Zacks Rank #5 (Strong Sell) rating.

Key Decisions for Investors

• Given the sharp downward revision to EPS guidance and the 'Strong Sell' analyst rating, investors holding long positions should re-evaluate their thesis due to significant near-term profitability headwinds.
• Investors should prioritize monitoring the company's medical loss ratio and management commentary on ACA and Medicaid cost trends, as stabilization in these areas is crucial for any potential turnaround.
• The divergence between strong revenue growth (+14% YoY) and declining profitability (-13% adj. EPS YoY) presents a clear risk; prospective long investors should exercise caution until there is evidence of margin stabilization, while short-sellers may view the current environment as validation of a bearish thesis.